Nurix Therapeutics Inc (NAS:NRIX)
$ 15.9 0.95 (6.35%) Market Cap: 970.97 Mil Enterprise Value: 698.12 Mil PE Ratio: 0 PB Ratio: 4.35 GF Score: 67/100

Nurix Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 11:45PM GMT
Release Date Price: $10.26 (-6.39%)
Eric Joseph
JPMorgan Chase & Co. - Moderator

Okay. We'll get started here. I'm Eric Joseph, senior biotech analyst at JPMorgan. Our next presenting company is Nurix Therapeutics, and it's my pleasure to welcome and introduce CEO, Arthur Sands, to bring us to the story. There's a Q&A after the presentation. So there will be mic runners in the room. And for those who are joining online, feel free to submit a question via the digital conference book. So with that, Arthur, please.

Arthur Sands
Nurix Therapeutics Inc - CEO

Thank you, Eric. And I'd like to thank the entire JPMorgan team for inviting us to the conference this year. It's very nice to be back, and I'm excited to tell you about Nurix, [how what we] accomplished in 2022, and what we look forward to in 2023. I will be making certain forward-looking statements. And so I refer you to our filings with the SEC regarding the risk factors that face our business.

So Nurix, we're focused on small molecule drug discovery centered on a very powerful cellular system known as the ubiquitin

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot